Olga Azevedo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5642544/publications.pdf

Version: 2024-02-01

1162367 1125271 14 237 8 13 citations h-index g-index papers 14 14 14 384 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Screening of Fabry Disease in Patients with Chest Pain Without Obstructive Coronary Artery Disease. Journal of Cardiovascular Translational Research, 2021, 14, 948-950.	1.1	2
2	Fabry Disease and the Heart: A Comprehensive Review. International Journal of Molecular Sciences, 2021, 22, 4434.	1.8	40
3	Massive myocardial calcification: a heart of stone!. European Heart Journal - Case Reports, 2021, 5, ytab362.	0.3	O
4	Fabry Disease Therapy: State-of-the-Art and Current Challenges. International Journal of Molecular Sciences, 2021, 22, 206.	1.8	35
5	Parkinson's Disease and Fabry Disease: Clinical, Biochemical and Neuroimaging Analysis of Three Pedigrees. Journal of Parkinson's Disease, 2020, 10, 141-152.	1.5	14
6	Founder effect of Fabry disease due to p.F113L mutation: Clinical profile of a late-onset phenotype. Molecular Genetics and Metabolism, 2020, 129, 150-160.	0.5	29
7	Specific Therapy for Transthyretin Cardiac Amyloidosis: A Systematic Literature Review and Evidenceâ€Based Recommendations. Journal of the American Heart Association, 2020, 9, e016614.	1.6	6
8	Clinical Features and Natural History of PRKAG2 Variant Cardiac Glycogenosis. Journal of the American College of Cardiology, 2020, 76, 186-197.	1.2	45
9	Natural history of the late-onset phenotype of Fabry disease due to the p.F113L mutation. Molecular Genetics and Metabolism Reports, 2020, 22, 100565.	0.4	20
10	Predictors of Fabry disease in patients with hypertrophic cardiomyopathy: How to guide the diagnostic strategy?. American Heart Journal, 2020, 226, 114-126.	1.2	5
11	Screening for Fabry disease in patients with left ventricular noncompaction. Revista Portuguesa De Cardiologia, 2019, 38, 709-716.	0.2	5
12	Inner ear involvement in Fabry disease: Clinical and audiometric evaluation of a large cohort of patients followed in a reference centre. European Journal of Medical Genetics, 2018, 61, 341-347.	0.7	14
13	New biomarkers defining a novel early stage of Fabry nephropathy: A diagnostic test study. Molecular Genetics and Metabolism, 2017, 121, 162-169.	0.5	14
14	Reduced glucosylceramide in the mouse model of Fabry disease: Correction by successful enzyme replacement therapy. Gene, 2014, 536, 97-104.	1.0	8